Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction

International Journal of Angiology

Volumn 16, Issue 1, 2007, Pages 12-16

  Whayne, Thomas F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Cardiovascular continuum; Coronary artery disease; Dysmetabolic syndrome; Endothelial dysfunction; Glitazones; Inflammation; Statins

Indexed keywords

EID: 80052992015     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1278237     Document Type: Article

References (37)

1. Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL investigators. Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-80 (Pubitemid 38541684)
2. Cannon C, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
3. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 (Pubitemid 40471450)
4. Ridker P. Inflammation in atherothrombosis: How to use highsensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J 2004;2(Suppl 1):4-9
5. Ridker PM, Cannon CP, Morrow D, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8
6. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-9
7. Oliveira GH. Novel serologic markers of cardiovascular risk. Curr Atheroscler Rep 2005;7:148-54
8. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34-42,94-103,148-56,215-25,273-81
9. Sytkowski PA, Kannel WB, DAgostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990;322:1635-41 (Pubitemid 20171587)
10. Feher MD, Caslake M, Foxton J, Cox A, Packard CJ. Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15:395-9 (Pubitemid 30066226)
11. Deb A, Caplice NM. Lipoprotein(a): New insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol 2004;27:258-64 (Pubitemid 38703073)
12. Gotto AM Jr. The new cholesterol education imperative and some comments on niacin. Am J Cardiol 1998;81:492-4 (Pubitemid 28106963)
13. Chai AU, Abrams J. Homocysteine: A new cardiac risk factor? Clin Cardiol 2001;24:80-4 (Pubitemid 32044548)
14. Berglund L, Ramakrishnan R. Lipoprotein(a): An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004;24:2219-26 (Pubitemid 39658021)
15. Shammas NW, Dippel E. Inflammation and cardiovascular risk: An overview. Int J Angiol 2004;13:161-7 (Pubitemid 41264555)
16. Sager PT, Melani L, Lipka L, et al; Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-8 (Pubitemid 37532562)
17. Koenig W, Khuseyinova N, Lwel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: Results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110:1903-8 (Pubitemid 39331899)
18. Davignon J. The cardioprotective effects of statins. Curr Atheroscler Rep 2004;6:27-35 (Pubitemid 38898907)
19. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074-95 (Pubitemid 36532579)
20. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104 (Pubitemid 39419498)
21. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 2005;27:1181-95 (Pubitemid 41393913)
22. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6 (Pubitemid 41697247)
23. Willenheimer R, Dahlf B, Rydberg E, Erhardt L. AT1-receptor blockers in hypertension and heart failure: Clinical experience and future directions. Eur Heart J 1999;20:997-1008 (Pubitemid 29306782)
24. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8 (Pubitemid 37093919)
25. Ferrari R. PERTINENT - PERindopril-Thrombosis, InflammatioN, Endothelial Dysfunction and Neurohormonal Activation Trial: A sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003;17:83-91 (Pubitemid 36903215)
26. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67
27. Spencer FA, Fonarow GC, Frederick PD, et al; National Registry of Myocardial Infarction. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: National registry of myocardial infarction. Arch Intern Med 2004;164:2162-8 (Pubitemid 39410807)
28. Conti CR. Can calcific aortic stenosis be prevented? Clin Cardiol 2002;25:201-2
29. Cowell SJ, Newby DE, Prescott RJ, et al; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97
30. Ninomiya JK, LItalien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42-6 (Pubitemid 38056019)
31. Castaño G, Menéndez R, Más R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002;22:89-99 (Pubitemid 36758536)
32. Wright CM, Zielke JC, Whayne TF Jr. Policosanol, an aliphatic alcohol sugarcane derivative: Use in patients intolerant of or inadequately responsive to statin therapy. Int J Angiol 2004;13:173-5 (Pubitemid 41264557)
33. Kelly P, Vasu S, Gelato M, McNurlan M, Lawson WE. Coenzyme Q10 improves myopathic pain in statin treated patients. American College of Cardiology Annual Scientific Session 2005. Orlando, March 6-9, 2005
34. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001;20:591-8
35. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: A systematic review. Ann Intern Med 2004;140:211-9
36. Wallerath T, Poleo D, Li H, Frstermann U. Red wine increases the expression of human endothelial nitric oxide synthase: A mechanism that may contribute to its beneficial cardiovascular effects. J Am Coll Cardiol 2003;41:471-8 (Pubitemid 36164505)
37. Maron DJ. Flavonoids for reduction of atherosclerotic risk. Curr Atheroscler Rep 2004;6:73-8 (Pubitemid 38898913)